Boehringer Ingelheim and Alpha Pharma Collaborate to localize the production of one of its Type 2 Diabetes Medicines in Saudi Arabia

Under the patronage of the Local Content and Government Procurement Authority, Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced today the successful transfer of manufacturing operations of one of its innovative medicines for the treatment of type 2 diabetes to Alpha Pharma in Saudi Arabia. This announcement follows Boehringer’s 2023 Memorandum of Understanding (MoU) with the Ministry of Investment, focusing on boosting cooperation in pharmaceutical localization and knowledge transfer to enhance the health of communities in the Kingdom. The collaboration with the leading Saudi pharmaceutical manufacturer, Alpha Pharma, aims to combat type 2 diabetes in the Kingdom and is fully aligned with the Kingdom’s Vision 2030 pillars. The announcement was formalized through a signing ceremony that took place in Jeddah with the presence of key representatives from the Ministry of Investment, the Ministry of Industry and Mineral Resources and National center for Industrial development, the Local Content and Government Procurement Authority, in addition to leadership figures from Alpha Pharma and Boehringer Ingelheim.

The medicine is used in the treatment of type 2 diabetes. As a research-driven company that believes in partnering for success, this collaboration reinforces Boehringer Ingelheim’s commitment to patient-centricity in Saudi Arabia where it takes a holistic view of the broader therapeutic needs in the field of interconnected cardio-renal-metabolic conditions, including type 2 diabetes. The partnership between Boehringer Ingelheim and Alpha pharma underscores the crucial role of a collaborative approach in improving treatment outcomes for patients and contributing to a healthier community.

Waleed Mashak, General Manager and Head of Human Pharma at Boehringer Ingelheim said, “Today marks a momentous occasion for both our company and Alpha Pharma as we stride forward in our journey of improving human health across the Kingdom. Aligned with Vision 2030 and Boehringer Ingelheim’s objectives, today’s announcement reflects our ongoing commitment to drive focused investments towards local manufacturing and bring cutting-edge medications to Saudi patients.” Mashak added: “transferring the production of our treatment to Saudi Arabia also means integrating Saudi talent further into the pharmaceutical industry, driving greater impact and building on our belief of partnering for success.”

Shaikh Yaser Al Naghi, Chairman of Alpha Pharma and Group CEO of Cigalah Healthcare said, “I am proud of the collaboration that Alpha Pharma has established with Boehringer Ingelheim. Localizing the manufacturing of an innovative medication by a leading global pharmaceutical firm marks an important milestone in our commitment to advancing healthcare accessibility in Saudi Arabia. By bringing the type 2 diabetes medication directly to patients in Saudi Arabia, we reinforce our dedication to improving health outcomes in the Kingdom.

Boehringer Ingelheim’s presence in Saudi Arabia dates back to the 1970s. As a research-driven company that develops breakthrough therapies to transform lives, the company is steadfast in its mission to build on its legacy and s Providing support in the field of cardio-renal-metabolic diseases, including type 2 diabetes.

-ENDS-

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com